{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T01:15:42Z","timestamp":1745370942905,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:00:00Z","timestamp":1637971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:00:00Z","timestamp":1637971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Eastern Finland (UEF) including Kuopio University Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>We investigated the drug use before and after transition to automated multi-dose dispensing (MDD) service among persons with Alzheimer\u2019s disease (AD) and compared whether the changes were similar in persons without AD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The register-based Finnish nationwide MEDALZ cohort includes 70,718 community-dwelling persons diagnosed with AD during 2005\u20132011. Each person who initiated MDD was matched in both groups with a comparison person without MDD by age, gender and for persons with AD, also time since AD diagnosis at the start of MDD. The study cohort included 15,604 persons with AD in MDD and 15,604 no-MDD, and 5224 persons without AD in MDD and 5224 no-MDD. Point prevalence of drug use was assessed every 3\u00a0months, from 1\u00a0year before to 2\u00a0years after the start of MDD and compared between persons in MDD to those who did not have MDD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>MDD was started on average 2.9 (SD 2.1) years after AD diagnosis. At the start of MDD, the prevalence of drug use increased especially for antipsychotics, antidepressants, opioids, paracetamol and use of\u2009\u2265\u200910 drugs among persons with and without AD. Prevalence of benzodiazepine use (from 12% 12\u00a0months before to 17% at start of MDD), memantine (from 29 to 46%) and\u2009\u2265\u20093 psychotropics (from 3.2 to 6.0%) increased among persons with AD. Decreasing trend was observed for benzodiazepine-related drugs, urinary antispasmodics and non-steroidal anti-inflammatory drugs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>MDD seems to be initiated when use of psychotropics is initiated and the number of drugs increases.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00228-021-03258-y","type":"journal-article","created":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T05:03:29Z","timestamp":1637989409000},"page":"513-521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Automated multi-dose dispensing in persons with and without Alzheimer\u2019s disease\u2014impacts on pharmacotherapy"],"prefix":"10.1007","volume":"78","author":[{"given":"Sanna","family":"Vallius","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Taipale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjaana","family":"Koponen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Maija","family":"Tolppanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antti","family":"Tanskanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirpa","family":"Hartikainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5069-5045","authenticated-orcid":false,"given":"Miia","family":"Tiihonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,27]]},"reference":[{"key":"3258_CR1","unstructured":"The Association of Finnish Pharmacies (2003) Annual review. Medicines in pre-packed doses. http:\/\/www.apteekkariliitto.fi\/media\/pdf\/annual_report_2003.pdf. Accessed 14 Dec\u00a02020"},{"key":"3258_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-2-1","volume":"2","author":"J Sinnem\u00e4ki","year":"2013","unstructured":"Sinnem\u00e4ki J, Sihvo S, Isoj\u00e4rvi J, Blom M, Airaksinen M, M\u00e4ntyl\u00e4 A (2013) Automated dose dispensing service for primary healthcare patients. Syst Rev 2:1. https:\/\/doi.org\/10.1186\/2046-4053-2-1","journal-title":"Syst Rev"},{"issue":"4","key":"3258_CR3","first-page":"3","volume":"24","author":"B Rechel","year":"2018","unstructured":"Rechel B (2018) Hub-and-spoke dispensing models for community pharmacies in Europe. Eurohealth 24(4):3\u20136","journal-title":"Eurohealth"},{"key":"3258_CR4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s11096-013-9899-0","volume":"36","author":"J Sinnem\u00e4ki","year":"2014","unstructured":"Sinnem\u00e4ki J, Saastamoinen LK, Hannula S et al (2014) Starting an automated dose dispensing service provided by community pharmacies in Finland. Int J Clin Pharm 36:345\u2013351","journal-title":"Int J Clin Pharm"},{"key":"3258_CR5","unstructured":"Ministry of Social Affairs (2016) L\u00e4\u00e4kkeiden potilaskohtaisen annosjakelun hyv\u00e4t toimintatavat. http:\/\/urn.fi\/URN:ISBN:978-952-00-3692-8. Accessed 14 Dec\u00a02020"},{"issue":"1","key":"3258_CR6","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/pds.3909","volume":"25","author":"M Tiihonen","year":"2016","unstructured":"Tiihonen M, Nyk\u00e4nen I, Ahonen R, Hartikainen S (2016) Discrepancies between in-home interviews and electronic medical records on regularly used drugs among home care clients. Pharmocoepidemiol Drug Saf 25(1):100\u2013105","journal-title":"Pharmocoepidemiol Drug Saf"},{"key":"3258_CR7","doi-asserted-by":"publisher","first-page":"871","DOI":"10.2165\/00002512-200825100-00006","volume":"25","author":"K Johnell","year":"2008","unstructured":"Johnell K, Fastbom J (2008) Concurrent use of anticholinergic drugs and cholinesterase inhibitors: register-based study of over 700,000 elderly patients. Drugs Aging 25:871\u2013877","journal-title":"Drugs Aging"},{"issue":"10","key":"3258_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026574","volume":"6","author":"C Sj\u00f6berg","year":"2011","unstructured":"Sj\u00f6berg C, Edward C, Fastbom J et al (2011) Association between multi-dose drug dispensing and quality of drug treatment - a register-based study. PLoS One 6(10):e26574. https:\/\/doi.org\/10.1371\/journal.pone.0026574","journal-title":"PLoS ONE"},{"issue":"6","key":"3258_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067088","volume":"8","author":"SM Wallerstedt","year":"2013","unstructured":"Wallerstedt SM, Fastbom J, Johnell K et al (2013) Drug treatment in older people before and after the transition to a multi-dose drug dispensing system - a longitudinal analysis. PLoS One 8(6):e67088. https:\/\/doi.org\/10.1371\/journal.pone.0067088","journal-title":"PLoS ONE"},{"issue":"9","key":"3258_CR10","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.sapharm.2018.11.007","volume":"15","author":"V Bobrova","year":"2019","unstructured":"Bobrova V, Hein\u00e4m\u00e4ki J, Honkanen O et al (2019) Older adults using multi-dose dispensing exposed to risks of potentially inappropriate medications. Res Social Adm Pharm 15(9):1102\u20131106","journal-title":"Res Social Adm Pharm"},{"key":"3258_CR11","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s11096-012-9662-y","volume":"34","author":"S Leikola","year":"2012","unstructured":"Leikola S, Tuomainen L, Peura S, Laurikainen A, Lyles A, Savela E, Airaksinen M (2012) Comprehensive medication review: development of a collaborative procedure. Int J Clin Pharm 34:510\u2013514","journal-title":"Int J Clin Pharm"},{"issue":"4","key":"3258_CR12","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/02813432.2017.1398933","volume":"35","author":"J Sinnem\u00e4ki","year":"2017","unstructured":"Sinnem\u00e4ki J, Airaksinen M, Valaste M et al (2017) Impact of the automated dose dispensing with medication review on geriatric primary care patients drug use in Finland: a nationwide cohort study with matched controls. Scan J Prim Health Care 35(4):379\u2013386","journal-title":"Scan J Prim Health Care"},{"key":"3258_CR13","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jad.2015.09.069","volume":"190","author":"Q-F Zhao","year":"2016","unstructured":"Zhao Q-F, Tan L, Wang H-F et al (2016) The prevalence of neuropsychiatric symptoms in Alzheimer\u2019s disease: systematic review and meta-analysis. J Affect Disord 190:264\u2013271","journal-title":"J Affect Disord"},{"key":"3258_CR14","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.jalz.2011.05.2410","volume":"7","author":"CG Lyketsos","year":"2011","unstructured":"Lyketsos CG, Carillo MC, Ryan JM et al (2011) Neuropsychiatric symptoms of Alzheimer\u2019s disease. Alzheimer & Dementia 7:532\u2013539","journal-title":"Alzheimer & Dementia"},{"key":"3258_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012100","author":"A-M Tolppanen","year":"2016","unstructured":"Tolppanen A-M, Taipale H, Koponen M, Lavikainen P, Tanskanen A, Tiihonen J, Hartikainen S (2016) Cohort profile: the Finnish Medication and Alzheimer\u2019s disease (MEDALZ) study. BMJ Open. https:\/\/doi.org\/10.1136\/bmjopen-2016-012100","journal-title":"BMJ Open"},{"key":"3258_CR16","unstructured":"Finnish Medical Society Duodecim, Current care guideline (2020) Memory disorders (in Finnish with English summary). https:\/\/www.kaypahoito.fi\/hoi50044. Accessed 14 Dec\u00a02020"},{"key":"3258_CR17","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M et al (1984) Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology 34:939\u2013944","journal-title":"Neurology"},{"key":"3258_CR18","unstructured":"American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders: DSM-IV. Washington (DC): Am Psychiatr Assoc"},{"key":"3258_CR19","unstructured":"World Health Organization, ATC\/DDD index (2021) https:\/\/www.whocc.no\/atc_ddd_index\/. Accessed 15 Dec\u00a02020"},{"key":"3258_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-015-0140-z","author":"A Tanskanen","year":"2015","unstructured":"Tanskanen A, Taipale H, Koponen M, Tolppanen A-M, Hartikainen S, Ahonen R, Tiihonen J (2015) From prescription drug purchases to drug use periods \u2013 a second generation method (PRE2DUP). BMC Med Inform Decis Mak. https:\/\/doi.org\/10.1186\/s12911-015-0140-z","journal-title":"BMC Med Inform Decis Mak"},{"key":"3258_CR21","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.euroneuro.2014.10.004","volume":"24","author":"H Taipale","year":"2014","unstructured":"Taipale H, Koponen M, Tanskanen A, Tolppanen AM, Tiihonen J, Hartikainen S (2014) High prevalence of psychotropic drug use among persons with and without Alzheimer\u2019s disease in Finnish nationwide cohort. Eur Neuropsychopharmacol 24:1729\u20131737","journal-title":"Eur Neuropsychopharmacol"},{"key":"3258_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afaa249","author":"LJ Seppala","year":"2020","unstructured":"Seppala LJ, Petrovic M, Jesper R et al (2020) STOPPFall (screening tool of older persons prescriptions in older adults with high fall risk): a Delphi study by the EuGMS task and Finish group on fall-risk-increasing drugs. Age Ageing. https:\/\/doi.org\/10.1093\/ageing\/afaa249","journal-title":"Age Ageing"},{"key":"3258_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4551","volume":"343","author":"C Coupland","year":"2011","unstructured":"Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippislaey-Cox J (2011) Antidepressant use and risk of adverse outcomes in older people: population based study. BMJ 343:d4551. https:\/\/doi.org\/10.1136\/bmj.d4551","journal-title":"BMJ"},{"key":"3258_CR24","doi-asserted-by":"publisher","first-page":"87.e15","DOI":"10.1016\/j.jamda.2016.09.019","volume":"18","author":"L Saarelainen","year":"2017","unstructured":"Saarelainen L, Tolppanen AM, Koponen M et al (2017) Risk of hip fracture in benzodiazepine users with and without Alzheimer\u2019s disease. J Am Med Dir Assoc 18:87.e15-87.e21. https:\/\/doi.org\/10.1016\/j.jamda.2016.09.019","journal-title":"J Am Med Dir Assoc"},{"key":"3258_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/1533317510390351","volume":"26","author":"V Mittal","year":"2011","unstructured":"Mittal V, Kurup L, Williamson D, Muralee S, Tampi RR (2011) Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence. Am J Alzheimers Dis Other Demen 26:10\u201328","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"14","key":"3258_CR26","doi-asserted-by":"publisher","first-page":"E519","DOI":"10.1503\/cmaj.160126","volume":"189","author":"H Taipale","year":"2017","unstructured":"Taipale H, Tolppanen AM, Koponen M et al (2017) Risk of pneumonia associated with incident benzodiazepine use among community-dwelling adults with Alzheimer disease. CMAJ 189(14):E519\u2013E529","journal-title":"CMAJ"},{"key":"3258_CR27","doi-asserted-by":"publisher","unstructured":"van Dalen-Kok AH, Pieper MJ, de Waal MW, Lukas A, Husebo BS, Achtenberg WP (2015) Association between pain, neuropsychiatric symptoms, and physical function in dementia. A systematic review and meta-analysis. BMC Geriatr 15. https:\/\/doi.org\/10.1186\/s12877-015-0048-6","DOI":"10.1186\/s12877-015-0048-6"},{"key":"3258_CR28","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/j.1532-5415.2008.01681.x","volume":"56","author":"KM Sink","year":"2008","unstructured":"Sink KM, Thomas J 3rd, Xu H, Craig B, Kritchevsky S, Sands LP (2008) Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc 56:847\u2013853","journal-title":"J Am Geriatr Soc"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03258-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-021-03258-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03258-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T04:16:47Z","timestamp":1644207407000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-021-03258-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,27]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["3258"],"URL":"https:\/\/doi.org\/10.1007\/s00228-021-03258-y","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2021,11,27]]},"assertion":[{"value":"21 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Heidi Taipale and Antti Tanskanen have participated in research projects funded by grants from Janssen-Cilag and Eli Lilly to their employing institution. Heidi Taipale reports personal fees from Janssen-Cilag.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}